Wedbush Downgrades Kinnate Biopharma to Neutral, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has downgraded Kinnate Biopharma from Outperform to Neutral and lowered the price target from $14 to $2.
September 19, 2023 | 10:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kinnate Biopharma has been downgraded from Outperform to Neutral by Wedbush, with a lowered price target from $14 to $2.
The downgrade from Outperform to Neutral and the significant reduction in price target by Wedbush analyst David Nierengarten could negatively impact investor sentiment and potentially lead to a decrease in Kinnate Biopharma's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100